You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Mental health, behavioural and neurodevelopmental conditions
  5. Dementia

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease

  • Technology appraisal guidance
  • Reference number: TA217
  • Published:  23 March 2011
  • Last updated:  20 June 2018
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: appendix A - GE decision paper - April 2015

TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: appendix A - GE decision paper - April 2015 TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: appendix A - GE decision paper - April 2015
27 April 2015
(120.27 Kb 35 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 28 April 2015

Back to top